ZA201308329B - Radiolabelled glutaminyl cyclase inhibitors - Google Patents

Radiolabelled glutaminyl cyclase inhibitors

Info

Publication number
ZA201308329B
ZA201308329B ZA2013/08329A ZA201308329A ZA201308329B ZA 201308329 B ZA201308329 B ZA 201308329B ZA 2013/08329 A ZA2013/08329 A ZA 2013/08329A ZA 201308329 A ZA201308329 A ZA 201308329A ZA 201308329 B ZA201308329 B ZA 201308329B
Authority
ZA
South Africa
Prior art keywords
glutaminyl cyclase
cyclase inhibitors
radiolabelled
radiolabelled glutaminyl
inhibitors
Prior art date
Application number
ZA2013/08329A
Other languages
English (en)
Inventor
Ulrich Heiser
Daniel Ramsbeck
Hans-Ulrich Demuth
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of ZA201308329B publication Critical patent/ZA201308329B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ZA2013/08329A 2011-05-27 2013-11-06 Radiolabelled glutaminyl cyclase inhibitors ZA201308329B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490654P 2011-05-27 2011-05-27
PCT/EP2012/059649 WO2012163773A1 (en) 2011-05-27 2012-05-24 Radiolabelled glutaminyl cyclase inhibitors

Publications (1)

Publication Number Publication Date
ZA201308329B true ZA201308329B (en) 2015-02-25

Family

ID=46149465

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/08329A ZA201308329B (en) 2011-05-27 2013-11-06 Radiolabelled glutaminyl cyclase inhibitors

Country Status (14)

Country Link
US (2) US8945510B2 (enExample)
EP (1) EP2714098A1 (enExample)
JP (1) JP2014515364A (enExample)
KR (1) KR20140028076A (enExample)
CN (1) CN103561776B (enExample)
AU (1) AU2012264951A1 (enExample)
BR (1) BR112013030341A2 (enExample)
CA (1) CA2835014A1 (enExample)
EA (1) EA028533B1 (enExample)
IL (1) IL229187A (enExample)
MX (1) MX2013013946A (enExample)
SG (2) SG194770A1 (enExample)
WO (1) WO2012163773A1 (enExample)
ZA (1) ZA201308329B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014140279A1 (en) 2013-03-15 2014-09-18 Probiodrug Ag Novel inhibitors
CN104230778B (zh) * 2014-07-14 2017-01-04 大连大学 β-烃氧酰基-γ-烃基-N-烃基-γ-丁内酰胺的合成方法
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
EP3830093A1 (en) 2018-07-27 2021-06-09 Biotheryx, Inc. Bifunctional compounds as cdk modulators
KR102230832B1 (ko) * 2019-06-17 2021-03-24 (주) 메디프론디비티 N-치환된 티오우레아 또는 우레아 유도체 및 이를 유효성분으로 함유하는 글루타미닐 사이클레이즈 활성 관련 질환의 예방 또는 치료용 약학적 조성물
EP4076657A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
EP4076661A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT712759A (enExample) 1963-01-09
US5304367A (en) * 1990-11-16 1994-04-19 New York University In vivo brain imaging agent and method for diagnosis of psychiatric disorders
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
KR101099206B1 (ko) * 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
US8703096B2 (en) 2006-04-21 2014-04-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Beta-amyloid PET imaging agents
WO2008055945A1 (en) * 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
NZ590658A (en) * 2008-07-31 2012-07-27 Probiodrug Ag Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases
EP2344157B1 (en) 2008-09-04 2016-05-25 Probiodrug AG Novel inhibitors
EP2411057B1 (en) 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
ES2548913T3 (es) * 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)

Also Published As

Publication number Publication date
JP2014515364A (ja) 2014-06-30
BR112013030341A2 (pt) 2016-11-29
CN103561776A (zh) 2014-02-05
US9610368B2 (en) 2017-04-04
CA2835014A1 (en) 2012-12-06
US8945510B2 (en) 2015-02-03
EA201301334A1 (ru) 2014-05-30
SG10201604304RA (en) 2016-07-28
MX2013013946A (es) 2014-01-31
IL229187A0 (en) 2013-12-31
SG194770A1 (en) 2013-12-30
KR20140028076A (ko) 2014-03-07
IL229187A (en) 2017-04-30
US20120301398A1 (en) 2012-11-29
WO2012163773A1 (en) 2012-12-06
EA028533B1 (ru) 2017-11-30
CN103561776B (zh) 2016-08-31
NZ617581A (en) 2016-03-31
US20150104389A1 (en) 2015-04-16
EP2714098A1 (en) 2014-04-09
AU2012264951A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
IL273079B (en) Heterocycloamines as pi3k inhibitors
ZA201308329B (en) Radiolabelled glutaminyl cyclase inhibitors
ZA201307016B (en) Glucosylceramide synthase inhibitors
HUE048834T2 (hu) Kináz inhibitorok
ZA201404156B (en) Kinase inhibitors
EP2782580A4 (en) SELECTIVE INHIBITORS OF KINASES
IL229028A0 (en) Kinase inhibitors
GB201009731D0 (en) Kinase inhibitors
ZA201404157B (en) Kinase inhibitors
GB201112157D0 (en) New use of glutaminyl cyclase inhibitors
GB201018597D0 (en) Inhibitors
GB201120474D0 (en) Inhibitors
SG10201602022UA (en) Glucosylceramide synthase inhibitors